Study identifier:D0570C00005
ClinicalTrials.gov identifier:N/A
EudraCT identifier:2008-004448-35
CTIS identifier:N/A
A phase I, randomised, double-blind, placebo-controlled, parallel-group, single-centre study to investigate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of AZD3199 given once daily as inhaled formulation via Turbuhaler to Japanese healthy men
Healthy
Phase 1
Yes
AZD3199 Turbuhaler®, Placebo Turbuhaler®
Male
27
Interventional
20 Years - 45 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 Dry powder for oral inhalation | Drug: AZD3199 Turbuhaler® 240, 720 and 2160 μ g, single and multiple (o.d. for 12 days) |
Placebo Comparator: 2 Dry powder for oral inhalation | Drug: Placebo Turbuhaler® single and multiple (o.d. for 12 days) |